^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MKI67 (Marker of proliferation Ki-67)

i
Other names: MKI67, MIB-, PPP1R105, Marker of proliferation Ki-67
22d
Clinicopathological correlations in 38 cases of gastroenteropancreatic high-grade neuroendocrine neoplasms. (PubMed, Front Oncol)
Furthermore, ROC curve analysis highlighted the diagnostic significance of the positive expression of the immunohistochemical markers CLU, SSTR2, and RB in identifying NET G3. To guide more suitable treatment strategies, it is essential to develop and apply valuable and more targeted immunohistochemical and molecular pathological markers for a comprehensive analysis.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • CLU (Clusterin) • MKI67 (Marker of proliferation Ki-67)
|
BRAF V600E • BRAF V600 • TP53 expression
1m
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells. (PubMed, Hemasphere)
This combination induced replicative stress and caspase-mediated cell death and was highly effective in resistant/refractory patient samples with TP53 deletion and/or mutation and in TP53 -/- NCI-H929 xenografted NOD-scid IL2Rgamma mice. Our in vitro, ex vivo, and in vivo data provide the rationale for combined CTPS1 and ATR inhibition for the treatment of p53-deficient patients.
Journal
|
MKI67 (Marker of proliferation Ki-67) • CTPS1 (CTP Synthase 1)
|
TP53 mutation • TP53 deletion • TP53 R175H • TP53 expression
3ms
Revealing Cellular Heterogeneity and Key Regulatory Factors of Triple-Negative Breast Cancer through Single-Cell RNA Sequencing. (PubMed, Front Biosci (Landmark Ed))
The four epithelial cell subsets and two critical regulons identified based on the scRNA-seq data could help explore the underlying intratumoral heterogeneity molecular mechanism and develop effective therapies for TNBC.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • MKI67 (Marker of proliferation Ki-67) • XBP1 (X-box-binding protein 1) • ANXA3 (Annexin A3) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2) • SCD (Stearoyl-CoA Desaturase)
4ms
Radiotherapy for central neurocytoma: A multicentric retrospective study in France. (PubMed, Cancer Radiother)
The analysis showed that patients who underwent subtotal surgical resection, particularly when the tumour had a Ki67 index greater than 2%, had an increased risk of local recurrence. These patients could benefit from adjuvant radiotherapy.
Retrospective data • Journal
|
MKI67 (Marker of proliferation Ki-67)
4ms
Investigation of the relationship between COVID-19 and pancreatic cancer using bioinformatics and systems biology approaches. (PubMed, Medicine (Baltimore))
This study unveils potential shared pathogenic mechanisms between PC and COVID-19, offering novel insights for future research and therapeutic strategies for the treatment of PC and SARS-CoV-2 infection.
Journal
|
AURKB (Aurora Kinase B) • MKI67 (Marker of proliferation Ki-67) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • KIF4A (Kinesin Family Member 4A) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
|
dasatinib • etoposide IV • irinotecan • methotrexate
4ms
Repair Effect of Umbilical Cord Mesenchymal Stem Cells Embedded in Hydrogel on Mouse Insulinoma 6 Cells Injured by Streptozotocin. (PubMed, Polymers (Basel))
In addition, the expression of both nuclear antigen Ki67 for cell proliferation and insulin-related genes such as Pdx1 and MafA was increased in the repaired MIN-6 cells by UC-MSCs + hydrogel, suggesting that the repair effect promotes the proliferation of the injured MIN-6 cells. Compared with the use of UC-MSCs alone, UC-MSCs + hydrogel exhibit superior antioxidant stress resistance against injured MIN-6 cells, better proliferation effects and a longer survival time of UC-MSCs because the porous structure and hydrophilic properties of the hydrogel could affect the growth of cells and slow down their metabolic activities, resulting in a better repair effect on the injured MIN-6 cells.
Preclinical • Journal
|
IL10 (Interleukin 10) • MKI67 (Marker of proliferation Ki-67) • IL1B (Interleukin 1, beta) • PDX1 (Pancreatic And Duodenal Homeobox 1) • CAT (Catalase)
5ms
Fe3O4 and Fe3O4core Aushell-based Hyperthermia Reduces Expression of Proliferation Markers Ki-67, TOP2A and TPX2 in a Human Breast Cancer Cell Line. (PubMed, In Vivo)
Both Fe3O4core Aushell and Fe3O4 NPs exhibit increased cytotoxicity to the cancer cell line tested (SK-BR-3) compared to HEK293 cells. The down-regulation in SK-BR-3 cells of the three proliferative markers studied, Ki-67, TOP2A and TPX2, after incubation with NPs suggests that cells that survived thermal destruction were not actively proliferating.
Preclinical • Journal
|
TOP2A (DNA topoisomerase 2-alpha) • MKI67 (Marker of proliferation Ki-67)
5ms
Antiproliferative and Anti-Inflammatory Effects of the Polyphenols Phloretin and Balsacone C in a Coculture of T Cells and Psoriatic Keratinocytes. (PubMed, Int J Mol Sci)
In summary, the anti-inflammatory effects of phloretin were more pronounced than those of methotrexate and balsacone C. In addition, the expression of lymphocyte common antigen (CD45) was more similar to that of the healthy condition after using phloretin or methotrexate. Finally, phloretin stood out from the other compounds and appears promising for psoriasis treatment.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL2 (Interleukin 2) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • IL17A (Interleukin 17A) • IL1A (Interleukin 1, alpha) • MKI67 (Marker of proliferation Ki-67) • PCNA (Proliferating cell nuclear antigen) • IL1B (Interleukin 1, beta)
|
methotrexate
6ms
MKI67 with arterial hypertension predict a poor survival for prostate cancer patients, a real-life investigation. (PubMed, Clin Transl Oncol)
MKI67 expression predicts poor outcomes for overall mortality in prostate cancer and hypertension patients. Additionally, our cross-validated multivariate score, which includes MKI67, demonstrated accuracy efficacy of predicting prognosis.
Journal
|
MKI67 (Marker of proliferation Ki-67)
7ms
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67. (PubMed, Prostate)
This study highlights KI67 positivity in prostate biopsy as a strong predictor of abiraterone efficacy in advanced PCa. These insights will assist clinicians in anticipating clinical outcomes and refining treatment decisions for PCa patients.
Journal • Metastases
|
MKI67 (Marker of proliferation Ki-67)
|
abiraterone acetate
8ms
Spinster Homologue 2 Expression Correlates With Improved Patient Survival in Hepatocellular Carcinoma Despite Association With Lymph-Angiogenesis. (PubMed, World J Oncol)
SPNS2 levels were higher in normal liver compared to HCC, and inversely correlated with cancer cell proliferation and better survival. SPNS2 expression may be beneficial in HCC patients despite detrimental in-vitro effects.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MKI67 (Marker of proliferation Ki-67)
8ms
High Ki67 Gene Expression Is Associated With Aggressive Phenotype in Hepatocellular Carcinoma. (PubMed, World J Oncol)
High MKi67 gene expression identified highly proliferative HCC with aggressive biology involving classical pathways in cell cycle regulation and DNA repair, as well as poor overall oncologic outcomes. This suggests potential for personalized treatment strategies, but validation and refinement of these observations require further research to elucidate the underlying mechanisms and validate therapeutic targeting of these pathways in MKi67-high HCC tumors.
Journal
|
HRD (Homologous Recombination Deficiency) • IFNG (Interferon, gamma) • MKI67 (Marker of proliferation Ki-67)
|
HRD
9ms
DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma. (PubMed, Front Oncol)
Methylation of the MGMT promoter, which predicts the response to temozolomide, is a well-established prognostic marker for glioblastoma...Finally, we report that the expression of DIAPH3 is at least partially regulated by the methylation of three CpG sites in the promoter region. We propose that combining the DIAPH3 expression with MGMT methylation could offer a better prediction of survival and more adapted postsurgical treatment for patients with MGMT-methylated glioblastoma.
Journal
|
MGMT (6-O-methylguanine-DNA methyltransferase) • MKI67 (Marker of proliferation Ki-67) • DIAPH3 (Diaphanous Related Formin 3)
|
MGMT expression
|
temozolomide
10ms
Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. (PubMed, World J Clin Cases)
MKI67 expression was positively associated with the Gleason Score, T stage, and N stage and showed a strong diagnostic and prognostic ability in PCa.
Journal
|
MKI67 (Marker of proliferation Ki-67)
10ms
Rothia in Nonsmall Cell Lung Cancer is Associated With Worse Survival. (PubMed, J Surg Res)
NSCLC with Rothia was associated with worse survival but also with favorable oncological characteristics such as less cell proliferation and favorable tumor immune microenvironment. We cannot help but speculate that Rothia in NSCLC is associated with mortality unrelated to oncological characteristics.
Journal • IO biomarker
|
HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • MKI67 (Marker of proliferation Ki-67)
|
HRD
10ms
Cyclin A2 expression as predictive biomarker in muscle-invasive upper tract urothelial carcinoma. (PubMed, Urol Int)
Low CCNA2 expression is significantly associated with worse OS. Thus, CCNA2 might serve as potential biomarker in muscle-invasive UTUC and may be used to characterize a subset of patients having an unfavorable outcome and for future risk-assessment scores.
Journal
|
TP53 (Tumor protein P53) • CCNA2 (Cyclin A2) • MKI67 (Marker of proliferation Ki-67)
|
TP53 expression • CCNA2 expression • CCNA2 overexpression
11ms
The predictive efficacy of programmed cell death in immunotherapy of melanoma: A comprehensive analysis of gene expression data for programmed cell death biomarker and therapeutic target discovery. (PubMed, Environ Toxicol)
We also verified the relationship between the GCH1 and MKI67 expression by wet experiment. This model has high prediction accuracy in SKCM patients and can provide a reference for clinical treatment.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • STAT3 (Signal Transducer And Activator Of Transcription 3) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • MKI67 (Marker of proliferation Ki-67) • SLC7A11 (Solute Carrier Family 7 Member 11) • IRF2 (Interferon Regulatory Factor 2) • NOX4 (NADPH Oxidase 4) • XBP1 (X-box-binding protein 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • GCH1 (GTP Cyclohydrolase 1) • LIPT1 (Lipoyltransferase 1) • TFAP2A (Transcription Factor AP-2 Alpha) • TFAP2C (Transcription Factor AP-2 Gamma)
12ms
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki-67. (ASCO-GU 2024)
Our study revealed that KI67 positivity in prostate biopsy specimens was a robust predictor of abiraterone efficacy for patients with advanced PCa. Further validation using datasets from other centers is needed to strengthen the findings of our work.
Clinical • Metastases
|
MKI67 (Marker of proliferation Ki-67)
|
abiraterone acetate
12ms
Screening of potential key genes in esophageal cancer based on RBP and expression verification of HENMT1. (PubMed, Medicine (Baltimore))
Immunohistochemical results showed that HENMT1 was highly expressed in ESCA tissues and was positively correlated with the expression of MKI67. HENMT1 is related to the occurrence and prognosis of ESCA, and is also related to the infiltration of immune cells in ESCA tissue, which may provide a new idea for the targeted treatment of ESCA.
Journal
|
CD4 (CD4 Molecule) • MKI67 (Marker of proliferation Ki-67)
12ms
Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells. (PubMed, J Steroid Biochem Mol Biol)
We directly compared the effects of four progestins (medroxyprogesterone acetate (MPA), norethisterone acetate (NET-A), levonorgestrel (LNG) and drospirenone (DRSP)) to each other and the natural progestogen progesterone (P) on selected cancer hallmarks...Notably, the cytoplasmic PR was not needed for activation of the ERK1/2 pathway by the progestogens. Given that DRSP showed significantly lower proliferation than MPA and NET-A, and that it had no effect on breast cancer cell migration and colony formation, hormonal formulations containing the newer generation progestin DRSP may provide a better benefit/risk profile towards breast cancer than those containing the older generation progestins.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • CCND1 (Cyclin D1) • MKI67 (Marker of proliferation Ki-67)
|
ER positive
12ms
R-ISS Stage-Dependent Single-Cell Sequencing Analysis Uncovers Oncogenes and Potential Immunotherapeutic Targets in Multiple Myeloma (ASH 2023)
Importantly, their crosstalks with myeloid cells and PC identified several potential immunotargets such as SIRPA-CD47, and CD74-MIF, respectively. Collectively, this study provided an R-ISS-related single-cell MM atlas and revealed the clinical significance of novel PC clusters, as well as potential immunotargets in MM progression.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD74 (CD74 Molecule) • MKI67 (Marker of proliferation Ki-67) • PCNA (Proliferating cell nuclear antigen) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • NKG7 (Natural Killer Cell Granule Protein 7) • SIRPA (Signal Regulatory Protein Alpha)
|
PCNA expression
12ms
Enhancing Tamoxifen Therapy with α-Mangostin: Synergistic Antiproliferative Effects on Breast Cancer Cells and Potential Reduced Endometrial Impact. (PubMed, Pharmaceuticals (Basel))
In endometrial cells, AM decreased MKI-67 gene expression, while it reverted the 4-OH-TMX-dependent CCND1 upregulation. This study establishes the benefits of incorporating AM as a co-adjuvant for first-line ER+ breast cancer therapy.
Journal
|
ER (Estrogen receptor) • CCND1 (Cyclin D1) • BIRC5 (Baculoviral IAP repeat containing 5) • MKI67 (Marker of proliferation Ki-67)
|
ER positive • CCND1 expression • BIRC5 expression
|
tamoxifen
1year
Can intratumoral microRNA-125a levels be a prognostic biomarker of a ER-positive breast cancer patients? (SABCS 2023)
High miR-125a levels in tumors were associated with aggressive biology and worse survival, thus it can be a candidate for a prognostic biomarker in ER+/HER2- patients.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • MKI67 (Marker of proliferation Ki-67) • MIR125A (MicroRNA 125a)
|
HER-2 positive • ER positive • HER-2 negative • HER-2 expression • HER-2 underexpression • ER positive + HER-2 negative
1year
Comprehensive Molecular Profiling of Breast Cancer: A real-time PCR assay for identifying ESR1, PGR, ERBB2, MKI67 and a novel proliferative signature in core needle biopsies and resected invasive breast cancer tissues (SABCS 2023)
APIS Breast Cancer Subtyping Kit demonstrated a high level of concordance with standard of care IHC/FISH in assessing breast cancer biomarker status. These findings suggest that the APIS Breast Cancer Subtyping Kit provides highly precise and reproducible quantitative assessment of BC biomarkers and molecular subtypes. Inclusion and exclusion criteria
Biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MKI67 (Marker of proliferation Ki-67)
|
HER-2 amplification
|
APIS Breast Cancer Subtyping Kit
1year
Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy. (PubMed, Cancer Lett)
We conducted single-cell RNA-seq (scRNA-seq) analysis on a residual lesion from a MSI-H PDAC patient who received a radical operation after eight cycles of neoadjuvant treatment (nab-paclitaxel/gemcitabine plus pembrolizumab). We compared the receptor-ligand interactions between the two groups, and found that no checkpoint receptor-ligand pairs between T cells and tumor cells were identified in the residual lesion, while there were many checkpoint receptor-ligand pairs in the nontreated primary PDAC. In conclusion, our findings revealed the characteristics of residual lesion of advanced PDAC with MSI-H upon combination treatment of chemotherapy and immunotherapy, which might provide some valuable clues for solving the puzzle of ICI in PDAC.
Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability) • MKI67 (Marker of proliferation Ki-67) • PCNA (Proliferating cell nuclear antigen)
|
MSI-H/dMMR • PCNA expression
|
Keytruda (pembrolizumab) • gemcitabine • albumin-bound paclitaxel
1year
CD70/CD27 Signaling Promotes Expansion of Clonal Plasma Cells in Multiple Myeloma and Is a Promising Therapeutic Target in Advanced Disease (ASH 2023)
Moreover, different monoclonal antibodies (Abs) and Ab-derivates were tested including a CD70 blocking antibody (αCD70) and an antibody-dependent cell-mediated cytotoxicity (ADCC) optimized antibody (cusatuzumab, ArgenX) that activates FcγR-expressing effector cells to assess the therapeutic potential of targeting CD70 in MM... Our results indicate that CD70-expressing MM cells have a stem-cell like phenotype and propagate the disease. Targeting CD70 is a promising new therapy especially in advanced disease.
IO biomarker • Metastases
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • MKI67 (Marker of proliferation Ki-67)
|
CD70 expression • CD27 expression • CD70 overexpression
|
cusatuzumab (ARGX-110)
1year
A Real-time PCR Assay for Identifying ESR1, PGR, ERBB2, MKI67 and a Novel Proliferative Signature in Core Needle Biopsies and Resected Tissue from Patients with Invasive Breast Cancer (AMP 2023)
APIS Breast Cancer Subtyping Kit demonstrated a high level of concordance with standard of care methods (IHC/FISH) in assessing BC biomarker status. These findings suggest that the APIS Breast Cancer Subtyping Kit provides highly precise and reproducible quantitative assessment of biomarkers and molecular subtypes.
Clinical • Biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MKI67 (Marker of proliferation Ki-67)
|
APIS Breast Cancer Subtyping Kit
1year
Decoding meningioma heterogeneity and neoplastic cell-macrophage interaction through single-cell transcriptome profiling across pathological grades. (PubMed, J Transl Med)
Meningioma neoplastic cells' diverse types cause inter-sample heterogeneity and a wide range of functions. Some proliferative neoplastic cell may educate macrophages, which promotes tumorigenesis possibly through the MIF-CD74 interaction. It provides novel clues for future potential therapeutic avenues.
Journal
|
CD74 (CD74 Molecule) • TOP2A (DNA topoisomerase 2-alpha) • MKI67 (Marker of proliferation Ki-67)
|
TOP2A expression
1year
Effects of insulin-like growth factor-1 on the proliferation and apoptosis of stallion testicular cells under normal and heat stress culture conditions. (PubMed, Anim Reprod Sci)
These data confirm that heat stress in stallions decreases TC viability. These findings may help identify a basal IGF-1 level for TC proliferation and apoptosis during heat stress-induced testicular degeneration in stallions.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • IGF1 (Insulin-like growth factor 1) • MKI67 (Marker of proliferation Ki-67) • PCNA (Proliferating cell nuclear antigen) • BAK1 (BCL2 Antagonist/Killer 1)
1year
Pancreatic ductal adenocarcinoma with a high expression of alcohol dehydrogenase 1B is associated with less aggressive features and a favorable prognosis. (PubMed, Am J Cancer Res)
PDAC patients with a high ADH1B expression had better disease-specific survival (DSS) and overall survival (OS) and ADH1B was an independent prognostic biomarker for both DSS (HR = 0.89, 95% CI = 0.80-0.99, P = 0.045) and OS (HR = 0.90, 95% CI = 0.82-0.99, P = 0.044) in multivariate analysis. In conclusion, PDAC with high ADH1B expression had less cell proliferation and malignant features, along with higher immune cell infiltration, and had a better prognosis.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • MKI67 (Marker of proliferation Ki-67) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide)
|
TP53 mutation • KRAS mutation • HRD • TP53 mutation + KRAS mutation • KRAS mutation + TP53 mutation
1year
Dimethylarsinic acid induces bladder carcinogenesis via the amphiregulin pathway. (PubMed, Toxicol Lett)
RNA interference of human amphiregulin (AREG) expression in human urinary bladder cell lines T24 and UMUC3 decreased expression of AREG and its 6 target genes and decreased cell proliferation. These data suggest that Areg has an important role in DMA-induced rat bladder carcinogenesis.
Journal
|
AREG (Amphiregulin) • CCNA2 (Cyclin A2) • MKI67 (Marker of proliferation Ki-67) • PRC1 (Protein regulator of cytokinesis 1)
|
AREG expression
over1year
Enrollment closed • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • MKI67 (Marker of proliferation Ki-67)
|
Imfinzi (durvalumab) • ceralasertib (AZD6738)
over1year
Effect of LINC00174 on the Malignant Proliferation of Multiple Myeloma Cells and Its Related Mechanism (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
LINC00174 promotes the proliferation of MM cells and inhibits cell apoptosis by regulating the miR-150/ FOXP1 axis.
Journal
|
CASP3 (Caspase 3) • FOXP1 (Forkhead Box P1) • MKI67 (Marker of proliferation Ki-67) • MIR150 (MicroRNA 150)
over1year
High miR-200c expression is associated with suppressed epithelial-mesenchymal transition, TGF-β signaling and better survival despite enhanced cell proliferation in gastric cancer patients. (PubMed, Am J Cancer Res)
In conclusion, patients with high miR-200c expression GC had better survival despite association with aggressive tumor biology, such as high mutation rates, cell proliferation, and low cancer immunity. Given that low miR-200c GC was associated with hypoxia, angiogenesis, EMT and TGF-β signaling, we cannot help but speculate that the difference in survival by miR-200c expression may be at least partly due to the association between low miR-200c expression and aggressive biology.
Journal
|
HRD (Homologous Recombination Deficiency) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • MIR200C (MicroRNA 200c) • TGFB1 (Transforming Growth Factor Beta 1) • MKI67 (Marker of proliferation Ki-67)
|
HRD • miR-200-c overexpression • miR-200-c expression
over1year
Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer. (PubMed, Am J Cancer Res)
It was also observed that the glycolysis was higher in the metastatic sites than in the primary breast cancer and the survival was not affected by the metastatic sites. In conclusion, accelerated glycolysis is associated with cancer cell proliferation and worse survival in TNBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MKI67 (Marker of proliferation Ki-67)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
over1year
Combined expression of MKI67, FOXC1 and PDL1 is a pan-tumor tissue-agnostic predictor of PD1/PDL1 inhibitor efficacy in metastatic renal cell cancer: Validation in checkmate 009, 010 and 025 clinical trial cohorts (ESMO 2023)
Results In CM025 ORR prediction by MM was specific to the Nivolumab arm [ITT CR%=22.5%, PR CR%=41.8%, NR CR%-3.6% OR=19.4 (4.3- 87.8)95%CI, p<0.0001, n=111] and not the Everolimus arm [ITT CR%=4.6%, PR CR%=3.3%, NR CR%= 5.4%, n=109]. Conclusions Tracking multiple dimensions of cancer biology using our MM approach again proved its superiority in predicting PD1/PDL1 inhibitor efficacy in advanced/metastatic tumors, this time in mRCC patients. This approach merits further testing in prospective clinical trials.
Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor • Metastases
|
TMB (Tumor Mutational Burden) • MKI67 (Marker of proliferation Ki-67) • FOXC1 (Forkhead Box C1)
|
PD-L1 expression • PD-1 expression • FOXC1 expression
|
Opdivo (nivolumab) • everolimus
over1year
E2F target score is associated with cell proliferation and survival of patients with hepatocellular carcinoma. (PubMed, Surgery)
The E2F target score, associated with cancer aggressiveness and worse survival, could be used as a prognostic biomarker in patients with hepatocellular carcinoma.
Journal
|
HRD (Homologous Recombination Deficiency) • MKI67 (Marker of proliferation Ki-67)
|
HRD
over1year
CD70/CD27 SIGNALING PROMOTES THE EXPANSION OF CLONAL PLASMA CELL SUBSETS IN MULTIPLE MYELOMA (EHA 2023)
In this regard, different Abs and Ab-derivates were tested including a CD70 blocking antibody (αCD70) and an antibody-dependent cell-mediated cytotoxicity (ADCC) optimized antibody (cusatuzumab) that activates FcγR-expressing effector cells... Although the treatment options of MM have rapidly increased during the last years, MM remains an incurable disease that ultimately leads to death. Our results indicate that especially advanced MM stages express high levels of CD70. In addition, our results indicate that CD70/CD27 cell-autonomous signaling contributes to disease progression and therapy resistance and identifies CD70 as potential target in MM.
IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • MKI67 (Marker of proliferation Ki-67)
|
CD70 expression • CD27 expression • CD70 overexpression
|
cusatuzumab (ARGX-110)
over1year
Efficacy and preliminary dose studies of ultrasound-guided sclerotherapy with lauromacrogol for the treatment of implanted hepatic tumors in rabbits. (PubMed, J Gastrointest Oncol)
Large coagulative necrotic foci were observed in the central area of tumors in Groups B, D, and E. The experiment demonstrates that lauromacrogol can inhibit tumor growth in the rabbit VX2 tumor model and cause VX2 tumor cell apoptosis. The sclerosing effect of the 1.5-fold amount of lauromacrogol is equivalent to that of absolute ethanol, with little effect on normal liver tissue.
Preclinical • Journal
|
CASP3 (Caspase 3) • MKI67 (Marker of proliferation Ki-67)
over1year
Journal
|
CDK4 (Cyclin-dependent kinase 4) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CDK6 (Cyclin-dependent kinase 6) • CDK2 (Cyclin-dependent kinase 2) • MKI67 (Marker of proliferation Ki-67) • PCNA (Proliferating cell nuclear antigen) • MAPK8 (Mitogen-activated protein kinase 8) • MAPK9 (Mitogen-Activated Protein Kinase 9)
|
SP600125
over1year
Automated Molecular Subtyping of Breast Carcinoma Using Deep Learning Techniques. (PubMed, IEEE J Transl Eng Health Med)
Accurate automated molecular subtyping can speed up this pathology procedure, reduce pathologists' workload and associated costs, and facilitate targeted treatment to obtain better outcomes.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MKI67 (Marker of proliferation Ki-67)
almost2years
Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene. (PubMed, Exp Hematol Oncol)
Integrative single-cell analysis was performed on Ph-like ALL and Ph ALL patients, and revealed Ph-like specific B-cell subpopulations and shared malignant B cells characterized by the ectopic expression of the inhibitory receptor CLEC2D. Collectively, scRNA-seq of Ph-like ALL with a novel TPR-PDGFRB fusion gene provides valuable insights into the underlying heterogeneity associated with disease progression and offers useful information for the development of immunotherapeutic techniques in the future.
Journal • IO biomarker
|
PDGFRB (Platelet Derived Growth Factor Receptor Beta) • MKI67 (Marker of proliferation Ki-67)
|
PDGFRB fusion